Today: February 7, 2016, 9:47 am
  
Finance

DISHMAN, Worry on Cash Flow Continues - new market research report published

companiesandmarkets.com
companiesandmarkets.com
DISHMAN, Worry on Cash Flow Continues - a new market research report on companiesandmarkets.com

 

PR-Inside.com: 2014-03-14 09:09:01
Dishman Q3FY13 result was below than our estimates due to lower sales of Dishman Netherlands, resulting in 440 bps decline in EBITDA margins on sequential basis. Revenue of Dishman Netherlands declined by 14% as it is going through complete renovation and is expected to be operational by Q3FY14. Total revenue grew by 19% due to higher growth of Carbogen Amcis (up by 32%). Impact of forex remained neutral to the bottom-line.

Going forward in FY14 CRAMS as well as MM both may witness a modest growth. CRAMS will be impacted by decline in Eprosartan contractual demand, that would be more than offset by new contracts (API supply for an oncology drug and Tuberculosis drug to Astellas and JNJ respectively), while current renovation at Dishman Netherlands will slowdown the growth momentum of marketable molecule (MM) business. Company expects FY14 revenue to grow by 12-13% supported by ~Rs.800-1000m from generic business.

With Scheduled debt repayment of ~Rs.1b and Rs.1.5b in CY 2013 and CY 2014 respectively coupled with lower visibility of free cash flow generation, we continue to remain concerned about the fate of highly levered (operating and financial) business model of Dishman. The fact that the company is likely to repay the debt of ~Rs.1b in 2013 from the proceeds of the sale of SEZ land clearly signifies that company is not generating sufficient free cash flow to service its debt.

As the proposed sale of SEZ land has eliminated immediate debt repayment concerns (Rs.1b), we increase our target price from Rs.47 to Rs.62, while accounting for lower capax (Rs.500m) in FY14. We retain our underperform rating on Dishman.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Press Information


Published by
Mike King
London: +44 (0) 203 086 8600
e-mail
www.companiesandmarkets.com



# 476 Words
Related Articles
 
More From Finance
Investing.co.uk Announces New Trader Counsel Services
LONDON - Jan. 25, 2016 - British financial news source Investing.co.uk has announced that it will now be offering the [..]
Credit-Yogi.com Offers Free Advice For Getting Completely [..]
Everyone has some degree of debt to deal with. Some folks have a lot of it, and they need to [..]
Offshore Processing slashes credit card processing costs [..]
High risk and high volume merchants engaged in unconventional trades, such as Adult Content, Adult Goods, Online Casinos, Online [..]
Real-Estate-Yogi Offers Free Advice to Returning Veterans [..]
Veterans of the United States are returning from active duty and need places to live. It is up to lenders [..]
The Experts at Credit-Yogi.com Explain How to [..]
Foreclosures have gone through a decrease over the past decade, but that doesn’t mean they don’t still happen. People who [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.